Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MV-s-NAP in Metastatic Breast Cancer
NCT04521764Phase 1Recruiting
- Sponsor
- Mayo Clinic
- Start
- Sep 2020
- Primary completion
- Aug 2027
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label trial of MV-s-NAP in breast cancer (3 cohorts), sponsored by Mayo Clinic. Primary endpoints: Maximum Tolerated Dose at 21 days, Best Tumor Response up to 2 years and 3 more. Started Sep 2020; status: recruiting.
02
Drugs
MV-s-NAP
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04521764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04521764.